The catecholamines market is projected to grow from USD 4.9 billion in 2025 to USD 9.3 billion by 2035, at a CAGR of 6.7%. Epinephrine (adrenaline) will dominate with a 39.4% market share, while intravenous will lead the route of administration segment with a 42.7% share.